Introduction
Optimal ART for treatment-naive individuals must be safe, effective and durable. Although three-drug regimens are standard, recent preliminary data suggest that two-drug regimens may be safe and effective. 1, 2 In the pilot ACTG A5353 study, dolutegravir plus lamivudine was safe and efficacious through to week 24 in treatment-naive participants with a screening plasma HIV-1 RNA of 1000-500 000 copies/mL, with similar virological responses in those with a baseline HIV-1 RNA of 100 000 copies/mL or .100 000 copies/mL. 2 The PADDLE study, which restricted baseline HIV-1 RNA to 100 000 copies/mL and CD4! T cell (CD4) count to 200 cells/mm 3 , provided preliminary evidence of the durability of dolutegravir plus lamivudine treatment through week 96. 3 Here we present the durability of dolutegravir plus lamivudine, through week 48, in the population investigated in A5353.
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Patients and methods
The complete A5353 study procedures are described in the week 24 primary report. 2 Briefly, A5353 was a single-arm, open-label, phase II study in which treatment-naive adults with HIV-1 RNA ,500 000 copies/mL and no reverse transcriptase, integrase or major protease resistance mutations, as defined by the IAS-USA HIV Drug Resistance Mutation List, 4 received oral dolutegravir 50 mg and lamivudine 300 mg as separate tablets (ViiV Healthcare, Brentford, UK) once daily. There was no CD4 count eligibility criterion. Enrolment of at least 25% of participants with baseline HIV-1 RNA .100 000 copies/mL was pre-specified. During 52 weeks of follow-up, participants underwent clinical evaluations and laboratory safety, lipid, HIV-1 RNA and CD4 count measurements, as well as adherence assessments by self-reported 4 day recall. 5 Real-time HIV-1 drug resistance testing was performed in participants with confirmed virological failure along with retrospective testing of dolutegravir plasma levels if the viral failure occurred on study treatment.
This report focuses on the secondary study objectives of virological success, safety assessments, and changes in CD4 count and serum lipids at week 48. Virological success was defined as HIV-1 RNA ,50 copies/mL by FDA Snapshot criteria. Protocol-defined virological failure was confirmed HIV-1 RNA .400 copies/mL at week 16 or 20, or .200 copies/mL at week 24 or later. The proportion of participants with virological success was estimated using two-sided exact Clopper-Pearson 95% CI. Comparison between baseline HIV-1 RNA strata (100 000 versus .100 000 copies/mL) was carried out by Fisher's exact test. All P values were nominal, with no adjustment for multiple comparisons. All analyses were carried out using Statistical Analysis System (SAS), version 9.4 (SAS Institute, Cary, NC, USA).
Ethics
The local institutional review boards approved the study at each of the sites, and each participant provided written informed consent. The study was registered with ClinicalTrials.gov, number NCT02582684.
Results
The study enrolled 120 eligible participants, 87% were male with a median age of 30 years (IQR 24-41), and was racially diverse (40% black and 27% Latino). The median (IQR) baseline HIV-1 RNA was 4.61 (3.94-5.05 ) log 10 copies/mL and 37 (31%) participants had baseline HIV-1 RNA .100 000 copies/mL. The median (IQR) CD4 count was 387 (288-596) cells/mm 3 . One hundred (83%) participants completed study treatment per protocol whereas 20 (17%) prematurely discontinued the study treatment owing to inability to attend the clinic visits (n " 8), loss to follow-up (n " 7), noncompliance with treatment (n " 3), pregnancy (n " 1) or virological failure (n " 1).
At week 48, 102 of the 120 participants (85%; 95% CI 77%-91%) had virological success by FDA Snapshot (Table 1) . Virological success by baseline HIV-1 RNA stratum was similar with 29/37 participants (78%; 95% CI 62%-90%) in the .100 000 copies/mL stratum and 73/83 participants (88%; 95% CI 79%-94%) in the 100 000 copies/mL stratum achieving HIV-1 RNA ,50 copies/mL (P " 0.18). Using an ITT missing/off treatment " failure approach (ITT-F), 101 of the 120 participants (84%; 95% CI 76%-90%) achieved HIV-1 RNA ,50 copies/mL with no significant differences between the two baseline HIV-1 RNA strata ( Figure 1 ). Using an astreated approach, 101 of the 104 (97%; 95% CI 92%-99%) achieved HIV-1 RNA ,50 copies/mL, similarly with no significant differences between the HIV-1 RNA strata. At every visit, 87% or more of participants reported no missed doses in the four preceding days.
Six (5%) participants had virological non-success (HIV-1 RNA 50 copies/mL) at week 48. Two of these participants were on study treatment, one discontinued study treatment early and three were lost to follow-up/deemed non-adherent by site investigators. All of these participants had HIV-1 RNA ,50 copies/mL at one or more timepoints in the first 20 weeks of treatment, prior to virological rebound. Twelve (10%) participants did not have virological data during the week 48 visit evaluation window. Three of these participants had missing data and nine had discontinued study treatment due to loss to follow-up or pregnancy, all with HIV-1 RNA ,50 copies/mL at the last available timepoint. In addition to the three participants who experienced protocol-defined virological failure by week 24, 2 one participant had virological failure after week 24. This participant achieved HIV-1 RNA ,50 copies/mL by week 8 and was found to be pregnant at study week 20 (5 weeks post-conception). The participant's HIV-1 RNA was ,50 copies/mL and she was switched to raltegravir and tenofovir disoproxil fumarate/emtricitabine. The participant was non-adherent to the new regimen and virological failure occurred at study week 33 with an HIV-1 RNA of 5459 copies/mL. No reverse transcriptase or integrase region resistance mutations were detected. She remained viraemic through the remainder of her pregnancy despite further ART modification, and delivered at 37 weeks, via elective caesarean section, an HIV-negative girl with an ectopic kidney.
Sixteen (13.3%) participants experienced Grade 3 or greater adverse events which the site investigator categorized as related or possibly related to study treatment in 6 (5%) participants: change in creatinine clearance (n " 2), and one each of angio-oedema, paraesthesia, palpitations and suicidal ideation. There was no premature discontinuation of study treatment or study follow-up due to an adverse event.
Among all participants, the median CD4 count increased by 182 (IQR 104-284) cells/mm 3 whereas the median calculated creatinine clearance decreased by 10 (IQR #18 to 2) mL/min. The median Dolutegravir ! lamivudine week 48 results JAC changes in lipids were total cholesterol !10 (IQR #6 to 24) mg/dL, LDL cholesterol !3.5 (IQR #11 to 6) mg/dL and HDL cholesterol !6 (IQR 1-11) mg/dL, whereas there was no change in triglyceride levels (0, IQR #27 to 26 mg/dL).
Discussion
Although dolutegravir plus lamivudine demonstrated promising safety and efficacy at week 24 in ART-naive participants with screening plasma HIV RNA ,500 000 copies/mL, 2 week 48 is the standard timepoint for comparative evaluation of the safety, efficacy and durability of initial ART. Thus at week 48, virological success (HIV-1 RNA ,50 copies/mL by the FDA Snapshot criterion) was achieved in 85% of participants treated with dolutegravir plus lamivudine, with no significant differences between those whose pre-treatment HIV-1 RNA was above or below 100 000 copies/mL. These results were consistent in ITT, missing/off treatment " failure and as-treated analyses. These results were similar to the findings of larger, fully powered, randomized clinical trials. The week 48 efficacy of the US Department of Health and Human Services guideline-recommended bictegravir-, dolutegravir-, elvitegravir/cobicistat-or raltegravir-based three-drug regimens ranged from 86.1% to 92.4%. [6] [7] [8] [9] [10] [11] [12] It is reassuring that only one participant had virological failure between weeks 24 and 48 on dolutegravir plus lamivudine in this study. The participant was off dolutegravir plus lamivudine due to pregnancy and was on raltegravir-based three-drug therapy at the time of virological failure. There were no failures with HIV-1 drug resistance between week 24 and week 48. At week 24, as previously reported, one participant developed resistance mutations to the study drugs (R263R/K and M184V), 2 and additional virological analyses to evaluate minority variants and phenotyping are currently underway. Dolutegravir plus lamivudine was generally safe and well tolerated in this pilot study. No neural tube defects occurred in the baby that was exposed to dolutegravir in the first 5 weeks of pregnancy and, based on data from the Antiretroviral Pregnancy Registry, the renal defect was unlikely to be related to study treatment. [13] [14] [15] Our results are limited by the relatively small sample size, the lack of a comparator arm, short follow-up period and enrolment of few women and few participants with a CD4 count ,200 cells/mm 3 . Nevertheless, our results agree with the pooled analysis of the ongoing fully powered phase III clinical trials, GEMINI 1 and 2. In the GEMINI studies, dolutegravir plus lamivudine was noninferior to dolutegravir plus tenofovir disoproxil fumarate/emtricitabine at week 48 by FDA Snapshot; virological success 91% versus 93%; treatment difference #1.7% (95% CI #4.4% to 1.1%). 16 Similar to our study, women and individuals with CD4 counts ,200 cells/mm 3 were under-represented in the GEMINI studies. Among participants with CD4 counts ,200 cells/mm Nyaku et al.
